| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CKLFSF6 |
| Uniprot No | Q9NX76 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-183aa |
| 氨基酸序列 | MENGAVYSPTTEEDPGPARGPRSGLAAYFFMGRLPLLRRVLKGLQLLLSLLAFICEEVVSQCTLCGGLYFFEFVSCSAFLLSLLILIVYCTPFYERVDTTKVKSSDFYITLGTGCVFLLASIIFVSTHDRTSAEIAAIVFGFIASFMFLLDFITMLYEKRQESQLRKPENTTRAEALTEPLNA |
| 预测分子量 | 20,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CKLFSF6重组蛋白的模拟参考文献示例(仅供参考，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Expression and Functional Analysis of Recombinant CKLFSF6 in Tumor Microenvironment*
**作者**：Li, X. et al.
**摘要**：本研究成功在大肠杆菌系统中表达并纯化了重组CKLFSF6蛋白，发现其通过调节趋化因子受体信号通路抑制肿瘤细胞迁移，提示其潜在的抗肿瘤治疗价值。
2. **文献名称**：*CKLFSF6 Recombinant Protein Modulates Inflammatory Response in Macrophages*
**作者**：Wang, Y. et al.
**摘要**：通过体外实验证明，重组CKLFSF6蛋白可降低巨噬细胞中促炎因子(如TNF-α、IL-6)的表达，表明其在炎症性疾病中的调控作用。
3. **文献名称**：*Structural Characterization of Human CKLFSF6 and Its Interaction with Chemokine Receptors*
**作者**：Chen, J. et al.
**摘要**：利用重组CKLFSF6蛋白解析了其三维结构，并通过表面等离子共振技术(SPR)证实其与CCR3受体的特异性结合，为靶向药物设计提供依据。
---
**注意事项**：
- 以上为模拟参考文献，CKLFSF6的研究相对较少，实际文献需通过 **PubMed**、**Web of Science** 或 **Google Scholar** 以关键词“CKLFSF6 recombinant”“CKLFSF6 function”等检索。
- 若研究较新，可尝试结合“chemokine-like factor”“CKLF family”等扩展关键词。
- 部分研究可能仅涉及基因水平分析，重组蛋白相关文献需仔细筛选。
CKLFSF6 (Chemokine-like factor superfamily member 6) is a recombinant protein derived from the human CKLF gene family, which shares structural and functional similarities with chemokines but exhibits distinct biological roles. This protein belongs to the CKLF-like MARVEL transmembrane domain-containing (CMTM) family, a group of cytokines implicated in immune regulation, inflammation, and cellular communication. CKLFSF6 is characterized by a conserved MARVEL domain, which is critical for membrane association and protein-protein interactions, and a variable N-terminal region that may influence receptor binding specificity.
Recombinant CKLFSF6 is typically produced using prokaryotic (e.g., E. coli) or eukaryotic expression systems to ensure proper folding and post-translational modifications. Its production enables studies on its role in modulating immune responses, particularly in T-cell activation, macrophage polarization, and chemotaxis. Emerging evidence suggests its involvement in pathological conditions, including cancer progression, autoimmune disorders, and infectious diseases. For instance, CKLFSF6 has been linked to tumor microenvironment regulation, where it may promote angiogenesis or suppress antitumor immunity depending on context.
Despite its potential therapeutic relevance, the exact signaling mechanisms of CKLFSF6 remain unclear. It is hypothesized to interact with unidentified G-protein-coupled receptors (GPCRs) or other chemokine receptors, triggering downstream pathways like MAPK/ERK or PI3K/AKT. Current research focuses on elucidating its structure-function relationships, tissue-specific expression patterns, and crosstalk with other immune modulators. Challenges include optimizing recombinant protein stability for clinical applications and addressing species-specific functional variations. As a relatively understudied cytokine, CKLFSF6 represents a promising target for immunotherapy development and biomarker discovery.
×
